Evans, R. M. & Mangelsdorf, D. J. Nuclear receptors, RXR, and the Big Bang. Cell 157, 255–266 (2014).
Parks, D. J. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365–1368 (1999).
Schalm, S. W. et al. Diurnal serum levels of primary conjugated bile acids. Assessment by specific radioimmunoassays for conjugates of cholic and chenodeoxycholic acid. Gut 19, 1006–1014 (1978).
Hofmann, A. F. & Hagey, L. R. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J. Lipid Res. 55, 1553–1595 (2014).
Cowen, A. E., Korman, M. G., Hofmann, A. F. & Thomas, P. J. Plasma disappearance of radioactivity after intravenous injection of labeled bile acids in man. Gastroenterology 68, 1567–1573 (1975).
Hansen, H. H. et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. 20, 210 (2020).
Matsumoto, M. et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int. J. Exp. Pathol. 94, 93–103 (2013).
Fukumoto, Y. et al. Studies of alpha-napthylisothiocyanate-induced hepatic disturbance. Hepatogastroenterology 27, 457–464 (1980).
Fickert, P. et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am. J. Pathol. 171, 525–536 (2007).
Sanyal, A. J. et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial. Nat. Med. 29, 392–400 (2023).
Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956–965 (2015).
Holt, J. A. et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581–1591 (2003).
Han, S. et al. Circadian control of bile acid synthesis by a KLF15-Fgf15 axis. Nat. Commun. 6, 7231 (2015).
Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217–225 (2005).
Sherman, C. A. & Hanson, R. F. Bile acid biosynthesis: the metabolism of 7 alpha-hydroxy-4-cholesten-3-one in the bile fistula rat. Steroids 27, 145–153 (1976).
Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. J. Am. Med. Assoc. 323, 844–853 (2020).
Thomas, D. W. et al. Clinical Development Success Rates 2006-2015 (Biotechnology Innovation Organization, Biomedtracker, Amplion, 2016).
Arrowsmith, J. & Miller, P. Trial watch: phase II and phase III attrition rates 2011–2012. Nat. Rev. Drug Discov. 12, 569 (2013).
Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191–200 (2012).
Derendorf, H. & Meibohm, B. Modeling of Pharmacokinetic/pharmacodynamic (pk/pd) relationships: concepts and perspectives. Pharm. Res. 16, 176–185 (1999).
Kuipers, F., Bloks, V. W. & Groen, A. K. Beyond intestinal soap–bile acids in metabolic control. Nat. Rev. Endocrinol. 10, 488–498 (2014).
Li, T. & Chiang, J. Y. L. Bile acids as metabolic regulators: an update. Curr. Opin. Gastroenterol. 39, 249–255 (2023).
de Aguiar Vallim, T. Q., Tarling, E. J. & Edwards, P. A. Pleiotropic roles of bile acids in metabolism. Cell Metab. 17, 657–669 (2013).
Feng, Y. et al. Integrative analysis of non12-hydroxylated bile acid revealed the suppressed molecular map of alternative pathway in nonalcoholic steatohepatitis mice. FASEB J. 38, e70167 (2024).
Tanaka, A. Current understanding of primary biliary cholangitis. Clin. Mol. Hepatol. 27, 1–21 (2021).
Fickert, P. et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J. Hepatol. 60, 1290–1303 (2014).
Chiang, J. Y. L. Bile acid metabolism and signaling in liver disease and therapy. Liver Res. 1, 3–9 (2017).
Pathak, P. et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J. Biol. Chem. 292, 11055–11069 (2017).
Xu, Y. et al. Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology 64, 1072–1085 (2016).
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M. & Trauner, M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 65, 350–362 (2017).
Ferslew, B. C. et al. Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig. Dis. Sci. 60, 3318–3328 (2015).
Puri, P. et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 67, 534–548 (2018).
Petersen, M. C. & Shulman, G. I. Mechanisms of insulin action and insulin resistance. Physiol. Rev. 98, 2133–2223 (2018).
Myers, M. G. Jr, Leibel, R. L., Seeley, R. J. & Schwartz, M. W. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol. Metab. 21, 643–651 (2010).
Beuers, U., Trauner, M., Jansen, P. & Poupon, R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J. Hepatol. 62, S25–S37 (2015).
Chiang, J. Y. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 23, 443–463 (2002).
Ding, L., Yang, L., Wang, Z. & Huang, W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm. Sinica. B 5, 135–144 (2015).
Wang, K., Zhang, Y., Wang, G., Hao, H. & Wang, H. FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid. Med. Res. Rev. 44, 568–586 (2024).
Trauner, M. et al. PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis. BMC Gastroenterol. 23, 75 (2023).
Patel, K. et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology 72, 58–71 (2020).
Adorini, L. & Trauner, M. FXR agonists in NASH treatment. J. Hepatol. 79, 1317–1331 (2023).
Tully, D. C. et al. Discovery of Tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J. Med. Chem. 60, 9960–9973 (2017).
Badman, M. K. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non-bile acid FXR agonist tropifexor (LJN452) in healthy volunteers. Clin. Pharmacol. Drug Dev. 9, 395–410 (2020).
Alkhouri, N. et al. Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. Liver Int. 44, 966–978 (2024).
Bledsoe, R. K. et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110, 93–105 (2002).
Xu, H. E. et al. Molecular recognition of fatty acids by peroxisome proliferator–activated receptors. Mol. Cell 3, 397–403 (1999).
Gampe, R. T. et al. Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 5, 545–555 (2000).
Jiang, L. et al. Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor. Biochem. Biophys. Res. Commun. 534, 1047–1052 (2021).
Edwards, J. E. et al. Modeling and experimental studies of obeticholic acid exposure and the impact of cirrhosis stage. Clin. Transl. Sci. 9, 328–336 (2016).
Bu, H. Z. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. Cur. Drug Metabol. 7, 231–249 (2006).
Koyama, K., Muto, I., Yamauchi, H., Takagi, Y. & Anezaki, T. Biochemical study of fibrosis in the rat liver in biliary obstruction. Tohoku J. Exp. Med. 116, 161–172 (1975).
Tsuchida, T. et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J. Hepatol. 69, 385–395 (2018).
Lu, T. T. et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6, 507–515 (2000).
de Aguiar Vallim, T. Q. et al. MAFG is a transcriptional repressor of bile acid synthesis and metabolism. Cell Metab. 21, 298–311 (2015).
Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J. & Suchy, F. J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276, 28857–28865 (2001).
Wang, M. N. et al. Bioequivalence and pharmacokinetic profiles of generic and branded obeticholic acid in healthy chinese subjects under fasting and Fed conditions. Drug Des. Devel. Ther. 15, 185–193 (2021).
Bass, J. & Lazar, M. A. Circadian time signatures of fitness and disease. Science 354, 994–999 (2016).
Takahashi, J. S. Transcriptional architecture of the mammalian circadian clock. Nat. Rev. Genet. 18, 164–179 (2017).
